Teltow / Leipzig, 29 April 2022 – Professor Hans-B. Bauerfeind has informed the company that he is resigning from his chairmanship of the Supervisory Board for health reasons at the age of 81 and is retiring from the Supervisory Board with immediate effect. The office of Chairman of the Supervisory Board will be taken over by Mr Thommy Stählin, long-time member of the Supervisory Board and former Deputy Chairman of the Supervisory Board.
The Executive Board and Supervisory Board would like to thank Professor Bauerfeind for his many years of activity on the Supervisory Board, with which he played a decisive role in shaping the development of the company.
Tilman Bur, CEO of CO.DON AG: "Professor Bauerfeind has accompanied CO.DON AG for many years. In addition to his outstanding financial commitment as an anchor shareholder, he has always been an important advisor and guide to CO.DON AG over the past years with his extensive experience. On behalf of the entire CO.DON AG, I would like to thank Professor Bauerfeind, whose work as Chairman of the Supervisory Board was characterised by dynamism and commitment. We wish him all the best for the future."
CO.DON AG develops, produces and distributes autologous cell therapies for the minimally invasive repair of cartilage defects. The product being marketed is a cell therapy product for the minimally invasive treatment of cartilage damage in the knee joint that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON's method is currently used in over 200 clinics in Germany and more than 17,000 patients have already been treated. In July 2017 CO.DON AG received central EU marketing authorisation for this product, followed by the marketing authorization for Switzerland in March 2019. At the Leipzig site, CO.DON has built one of the largest facilities for the production of human cells on an industrial scale for in-house and contract manufacturing. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A3E5C08). Executive Board: Tilmann Bur.
Further information is available from www.codon.de.
Director Corporate Communications
Investor Relations / Public Relations
T: +49 (0)341 99190 330
F: +49 (0)341 99190 309